How much funding has Ingenix raised?

Ingenix has raised $24.7M in total funding. Their latest funding round was Seed. Key investors include Sofinnova Partners, Inovo VC, OTB VC, IFC.

Where is Ingenix headquartered?

Ingenix is headquartered in Warsaw, Poland. The company has a team of 11-50 people.

What does Ingenix do?

Ingenix operates in the AI in Biotech / Drug Discovery sector. Warsaw-based AI-biology company building the Biological Reasoning Engine, which uses Modality Fusion to reason across biological data modalities and scales for translational and clinical R&D decisions. An AI reasoning engine that fuses best-in-class specialist models across biological modalities and scales and reasons over their representations directly. Every output comes with a reasoning trace covering mechanism, evidence and caveats, to de-risk drug development decisions.

When was Ingenix founded?

Ingenix was founded in 2023. It is based in Warsaw, Poland.

How much funding has Ingenix raised?

Ingenix has raised $24.7M in total funding. Key investors include Sofinnova Partners, Inovo VC, OTB VC, IFC.

Who is the CEO of Ingenix?

Piotr Surma is the CEO of Ingenix. The company was founded in 2023.

Where is Ingenix located?

Ingenix is headquartered in Warsaw, Poland.

What funding stage is Ingenix at?

Ingenix is currently at the Seed stage.

How many employees does Ingenix have?

Ingenix has approximately 11-50 employees.

Ingenix

Category: AI in Biotech / Drug Discovery

Warsaw-based AI-biology company building the Biological Reasoning Engine, which uses Modality Fusion to reason across biological data modalities and scales for translational and clinical R&D decisions. Ingenix was founded in 2023. The company is led by Piotr Surma. Based in Warsaw, Poland. Team size: 11-50. Total funding raised: $24.7M. Latest round: Seed. Key investors include Sofinnova Partners, Inovo VC, OTB VC, IFC.

Founded: 2023
Headquarters: Warsaw, Poland
Team size: 11-50
Total funding: $24.7M

Value proposition

An AI reasoning engine that fuses best-in-class specialist models across biological modalities and scales and reasons over their representations directly. Every output comes with a reasoning trace covering mechanism, evidence and caveats, to de-risk drug development decisions.

Products and solutions

Biological Reasoning Engine (built on Modality Fusion), Thalamus Reasoning (9B-parameter model), Thalamus Decision (open-source version released 9 Nov 2026), Qualified Access Program (launched June 2026), a 95B-parameter model is in development.

Unique value

Modality Fusion: an architecture that integrates specialist models across modalities and biological scales, rather than training one giant model. Thalamus Reasoning reportedly encodes omics data as compact vectors (about 4 tokens per profile).

Target customer

Pharma and biotech R&D teams with translational and clinical questions (via the Qualified Access Program); academic and commercial researchers (via the open-source Thalamus Decision model).

Industries served

Pharma, biotech, drug discovery and development, oncology, cellular aging research

Technology advantage

Founding team from Applica (acquired by Snowflake) with multimodal LLM expertise, plus pharma scientists with experience from discovery through Phase II. Company-reported LongevityBench results: rank 1 of 29 models, mean rank 1.42, with no benchmark data used in training. These results have not been independently verified.

How they differentiate

Fuses many specialist models and reasons across modalities with explainable traces, rather than scaling a single foundation model. Small focused team with a 9B model claiming to beat frontier LLMs on a domain benchmark.

Main competitors

Insilico Medicine, Recursion, Inceptive

Major milestones

2023: founded by Piotr Surma and Adam Dancewicz, Apr 2025: €9M seed, Jun 2026: €13M seed extension led by Sofinnova and launch of the Qualified Access Program, 9 Nov 2026: Thalamus Reasoning claimed first place on LongevityBench and Thalamus Decision open-sourced.

Growth metrics

About 42 employees as of Sep 2026 (Tracxn)

Market positioning

Early-stage European TechBio company positioned as the reasoning layer for translational and clinical R&D decisions, with an open-source release to build trust.

Geographic focus

Global; pharma and biotech partners in Europe and beyond

About Piotr Surma

Co-founder and former CEO of Applica (document-understanding AI company acquired by Snowflake in 2022; its TILT model contributed to the GPT-4 benchmark); studied at IMT Atlantique.

Latest news about Ingenix

Ingenix releases Thalamus Decision for cellular aging research

More AI in Biotech / Drug Discovery companies

Official website: https://ingenix.ai